Search research articles
Contact Us
Filters
Showing results (11-20 of 392) with videos related to
Page
of 40
Sort By:
Cell Cycle (Georgetown, Tex.)
|
June 23, 2005
TELAML1-positive ALL: a discordant genotype
Monique L den Boer, William E Evans, Rob Pieters
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|
February 16, 2006
Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases
Inge M Appel, Wim C J Hop, Rob Pieters
Seminars in Fetal & Neonatal Medicine
|
April 19, 2012
Diagnosis and management of neonatal leukaemia
Marieke H van der Linden, Sara Creemers, Rob Pieters
British Journal of Haematology
|
February 1, 2006
Towards targeted therapy for infant acute lymphoblastic leukaemia
Ronald W Stam, Monique L den Boer, Rob Pieters
Pediatric Blood & Cancer
|
April 5, 2008
Perceived and actual motor competence of children treated for cancer with vincristine containing chemotherapy
Annelies Hartman, Rob Pieters, Cor van den Bos, et al.
Pediatric Blood & Cancer
|
September 24, 2015
Ammonia Levels Should Not Be Used as a Surrogate Marker of Levels of Asparaginase Activity in Acute Lymphoblastic Leukemia Patients
Wing H Tong, Rob Pieters, Inge M van der Sluis
Pediatric Blood & Cancer
|
September 1, 2007
Decrease in peripheral muscle strength and ankle dorsiflexion as long-term side effects of treatment for childhood cancer
Annelies Hartman, Cor van den Bos, Theo Stijnen, et al.
Cancer
|
February 3, 2006
Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine
Annelies Hartman, Cor van den Bos, Theo Stijnen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 18, 2021
How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review
Leiah J Brigitha, Rob Pieters, Inge M van der Sluis
Haematologica
|
June 3, 2016
HOXA-activated early T-cell progenitor acute lymphoblastic leukemia: predictor of poor outcome?
Jules Pp Meijerink, Kirsten Canté-Barrett, Eric Vroegindeweij, et al.
Page
of 40
Search research articles
Search
Showing results (11-20 of 392) with videos related to
Sort By:
Page
of 40
Cell Cycle (Georgetown, Tex.)
|
June 23, 2005
TELAML1-positive ALL: a discordant genotype
Monique L den Boer, William E Evans, Rob Pieters
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|
February 16, 2006
Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases
Inge M Appel, Wim C J Hop, Rob Pieters
Seminars in Fetal & Neonatal Medicine
|
April 19, 2012
Diagnosis and management of neonatal leukaemia
Marieke H van der Linden, Sara Creemers, Rob Pieters
British Journal of Haematology
|
February 1, 2006
Towards targeted therapy for infant acute lymphoblastic leukaemia
Ronald W Stam, Monique L den Boer, Rob Pieters
Pediatric Blood & Cancer
|
April 5, 2008
Perceived and actual motor competence of children treated for cancer with vincristine containing chemotherapy
Annelies Hartman, Rob Pieters, Cor van den Bos, et al.
Pediatric Blood & Cancer
|
September 24, 2015
Ammonia Levels Should Not Be Used as a Surrogate Marker of Levels of Asparaginase Activity in Acute Lymphoblastic Leukemia Patients
Wing H Tong, Rob Pieters, Inge M van der Sluis
Pediatric Blood & Cancer
|
September 1, 2007
Decrease in peripheral muscle strength and ankle dorsiflexion as long-term side effects of treatment for childhood cancer
Annelies Hartman, Cor van den Bos, Theo Stijnen, et al.
Cancer
|
February 3, 2006
Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine
Annelies Hartman, Cor van den Bos, Theo Stijnen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 18, 2021
How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review
Leiah J Brigitha, Rob Pieters, Inge M van der Sluis
Haematologica
|
June 3, 2016
HOXA-activated early T-cell progenitor acute lymphoblastic leukemia: predictor of poor outcome?
Jules Pp Meijerink, Kirsten Canté-Barrett, Eric Vroegindeweij, et al.
Page
of 40